Amgen Research (munich) Gmbh

Amgen Inc.

Micromet Ag

Boehringer Ingelheim International Gmbh

Immatics Biotechnologies Gmbh

Universiteit Gent

Vib Vzw

Amgen Research Gmbh

Tobias Raum

Peter Kufer

Patrick Hoffmann

Doris Rau

Ralf Lutterbüse

Roman Kischel

Elisabeth Nahrwold

Andreas Wolf

Claudia Blümel

Christoph Dahlhoff

Susanne Mangold

Ralf Lutterbuese

Jochen Pendzialek

Susanne Hipp

Johannes Brozy

Barbara Hebeis

Benno Rattel

Markus Münz

Matthias Friedrich

Evelyne Schaller

Eric Borges

Paul Adam

Cornelius Pompe

Matthias Klinger

Shouhua Xiao

Dineli Wickramasinghe

Zheng Pan

Markus Muenz

Petra Fluhr

Pamela Bogner

Steven Zeman

Ines Herrmann

Chadwick Terence King

Holger Wesche

Bryan D Lemon

Birgit Kohleisen

Brian Mingtung Chan

M Shawn Jeffries

Meera Berry

Silke Mittelstrass

Julie Bailis

Sandra Bruckmaier

Alexander Murr

Monika Wissinger

Susanne Hausmann

Carola Steiger

Jonas Anlahr

Eva Krinner

Sonja Offner

Patrick Bäuerle

Bertram Weiss

Irwin Chen

Tara Arvedson

Olivier Nolan-Stevaux

Klaus Brischwein

Lisa Nahrwold

Sandra Ross

Julia Hepp (nee Henckel)

Eva Vieser (nee Krinner)

Silke Petsch (nee Mittelstrass)

Ruprecht Zierz

Julia Henckel

Ian Nevin Foltz

Patrick A Baeuerle

Walter C Fiers

Derek Evan Piper

Darren L Bates

Xavier Saelens

Ulla Lenkkeri-Schütz

Christian Itin

Agnieszka Kielczewska

Julia Hepp

Eva Vieser

Silke Petsch

Patrick Hoffman

Jens Hennecke

Petra Mayer

Bernd Schlereth

Ronny Cierpka

John Lumsden

Stefan Pflanz

Wibke Deisting

Jörg Volkland

Katrin Borschert

Florian Zettl

Franziska Bott

Marc Panzer

Lisa Winkel

Weihsu Claire Chen

Lars Gaedtke

Jonas Karl-Josef Honer

Wentao Chen

Claudia Bluemel

Heiko Schuster

Nathan William Pierce

Susmith Mukund

Ann-Lena Frisk

Provided are antibody constructs comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Also provided are nucleic acids encoding the antibody constructs, vectors comprising the nucleic acids, and host cells transformed or transfected with the vectors. Further provided are a process for the production of the antibody constructs, methods of using the antibody constructs and a kit comprising the antibody constructs.

Antibody constructs for CDH19 and CD3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.

Antibody constructs for DLL3 and CD3

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

PSMA and CD3 bispecific T cell engaging antibody constructs

The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.

MAGEB2 binding constructs

A bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. A nucleic acid comprising a polynucleotide encoding the antibody construct, a vector comprising the nucleic acid comprising the polynucleotide and a host cell transformed or transfected with the nucleic acid comprising the polynucleotide or vector. A process for the production of the antibody construct, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

Binding molecules for BCMA and CD3

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

Cross-species-specific PSMAxCD3 bispecific single chain antibody

The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.

Anti-CCR8 antibodies and uses thereof

The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and theCD3ε chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Bispecific antibody construct directed to MUC17 and CD3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3

The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

Cross-species-specific single domain bispecific single chain antibody

The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Bispecific antibody constructs for CDH3 and CD3

The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.

Compositions comprising cross-species-specific antibodies and uses thereof

Growing community of inventors

Munich, Germany

Tobias Raum